We previously reported the identification of a T cell epitope in the N-terminal part of the circumsporozoite protein (CSP) of Plasmodium yoelii yoelii (Pyy). CD4 ⍣ T cell clones derived from mice immunized with a 21-mer peptide (amino acids 59-79, referred to as Py1) containing this epitope confer complete protection after passive transfer in mice. These clones proliferate in vitro in the presence of a 13-mer peptide (amino acids 59-71, referred to as Py1T). This shorter peptide was found to behave as a T h epitope in vivo, allowing overcoming of the genetic restriction for production of anti-repeat antibodies in BALB/c mice, when cross-linked to three (QGPGAP) repeats of the Pyy CSP. In this study, we report protection in BALB/c mice, against a challenge with Pyy sporozoites after immunization with linear and multiple antigen peptides containing Py1T as T epitope and three repeats QGPGAP (Py3) as B epitope. Multiple antigen peptide (MAP4-Py1T-Py3)-induced immunity was shown to be more effective than immunity induced by the linear form of the conjugate (Py1T-Py3), protecting against challenges with higher numbers of sporozoites. In both cases, levels of anti-repeat antibodies were strongly correlated with anti-parasite antibodies and protection. When tested in vitro, sera from mice immunized with the protective constructs strongly inhibited Pyy liver stages, while lymph node T cells displayed no cytotoxicity. In vivo, depletion of CD4 ⍣ or CD8 ⍣ T cells did not affect protection. Furthermore, MAP4-Py1T-Py3-immunized mice were not protected against a challenge with P. yoelii nigeriensis sporozoites, a parasite which has the same Py1T sequence but differs from Pyy in its repeated sequence. These results demonstrate that anti-repeat antibodies raised by immunization with the linear or the MAP form are exclusively responsible for the protection. Furthermore, this antibody response is boosted by a sporozoite challenge, allowing protection against a second challenge.
Introduction
Extensive studies in rodent and human models demonstrated that protective immunity achieved by immunization with irradiated sporozoites involves antibodies and T cell effector mechanisms directed in part against the circumsporozoite protein (CSP), the major component of the surface of the antibody response in infected animals and man. Evidence for the neutralizing activity of anti-repeat antibodies has been demonstrated in vivo in murine models after passive transfer (3) (4) (5) (6) or after induction by synthetic peptides (7) . The best anti-repeat antibody responses and protection against a sporozoite challenge have been achieved with multiple antigen peptide (MAP). Protection against Plasmodium berghei infection and high levels of anti-repeat antibodies were obtained in mice immunized with a MAP containing defined T and B epitopes of the P. berghei CSP (8) (9) (10) . In the P. yoelii system, protective antibodies against the repeat region of the CSP were induced in mice immunized with a MAP including the P. yoelii CSP repeats and two T h epitopes from tetanus toxoid. However, use of these T h epitopes did not allow strains of mouse which do not respond to peptides containing only the repeats to resist efficiently to a rechallenge 6 weeks after the first challenge (11) .
Several findings have shown that T cells could participate in the effector mechanisms of the immune response to preerythrocytic stages. Depending on mouse and parasite strains, depletion of CD8 ϩ or CD4 ϩ T cells in mice immunized with irradiated sporozoites results in loss of protection against a sporozoite challenge (12) (13) (14) (15) (16) . Passive transfer of CD8 ϩ T cell clones directed against T epitopes identified in CSP of P. berghei and P. yoelii could confer protection against sporozoite-induced infection (17) (18) (19) (20) . In addition, protection in the absence of anti-sporozoite antibodies was reported after peptide immunization with a T epitope of P. berghei CSP, assembled as a MAP (10) .
We previously reported the identification of a T cell epitope in the N-terminal part of the CSP of P. yoelii yoelii 265 BY (Pyy) (21) . CD4 ϩ T cell clones were derived from mice immunized with a peptide of 21 amino acids corresponding to amino acid positions 59-79, referred as to Py1. These clones were able to inhibit in vitro hepatic development of the parasite and conferred complete protection after their passive transfer in mice (22) . Proliferation assays using truncated peptides showed that the epitope recognized by these cells was contained within the amino acid sequence from 59 to 71, referred to as Py1T (23, 24) . Py1T was found to behave as a T h epitope in vivo, allowing overcoming of the genetic restriction for production of anti-repeat antibodies in BALB/c mice when cross-linked to three (QGPGAP) repeats of the Pyy CSP (24) . Mice immunization with linear or branched constructs containing this epitope alone or coupled with repeats of the Pyy CSP induced T cells proliferating in vitro in the presence of any of these constructs (24) .
To allow for priming and boosting of vaccine-induced antibody response by exposure to sporozoite and for induction of a cytotoxic T cell response against infected hepatocytes, we performed immunizations in BALB/c mice with the Py1T epitope coupled with a B epitope contained in repeats of Pyy CSP. Immunization with linear peptide and MAP formulations induced protection against a Pyy sporozoite challenge. Effector mechanisms of this protection were investigated.
Methods

Peptides
The amino acid sequences of T and B epitopes from Pyy CSP and constructs containing these epitopes used in this study are represented in Fig. 1 . Peptides were produced according to the amino acid sequence reported by Lal et al. (25) and de la Cruz et al. (26) . They were synthesized as already described (27) . The products gave the correct theoretical values of amino acids and presented a single peak after HPLC analysis. The lyophilized material was resuspended in sterile distilled water at 10 or 5 mg/ml as stock solutions which were stored at -20°C until use.
Mice and immunization schedule
Female BALB/c and C3H/He mice (5-8 weeks old) purchased from Charles River (Saint Aubin-lè s-Elbeuf, France) were immunized at the base of the tail with 30 µg of peptide emulsified in complete Freund's adjuvant (Sigma, St Louis, MO). Mice were boosted twice with 30 µg of the same peptide emulsified in incomplete Freund's adjuvant (Sigma) 2 weeks after priming and then 1-2 weeks after. Control mice received only the adjuvant.
Parasites
Sporozoites of the 265 BY strain of P. yoelii yoelii (Pyy) and of P. yoelii nigeriensis, Killick-Kendrick, 1973 (Pyn), were obtained from infected salivary glands of Anopheles stephensi. After aseptic dissection, salivary glands were homogenized in a glass grinder and diluted in sterile culture medium for in vitro hepatocyte infestation or PBS for mice challenges. One week after the last boost, mice were challenged with 4000 or 50,000 sporozoites. Protection was defined as absence of parasite in Giemsa-stained blood smears from 4 to 12 days after challenge. Culture of malaria hepatic stages BALB/c hepatocytes were prepared as described, with minor modifications (28) . Cells were isolated by collagenase perfusion (Boehringer Mannheim, Mannheim, Germany) of liver fragments and were further purified over a 60% Percoll gradient (Pharmacia Biotech, Uppsala, Sweden). Hepatocyte purity and viability were Ͼ95% as assessed by Trypan blue dye exclusion. Cells (8ϫ10 4 ) were cultured in eight-chamber plastic Lab-Teck slides (Nunc, Naperville, IL) in William's E medium (Gibco, Irvine, UK) supplemented with 5% FCS (Gibco), 1% penicillin-streptomycin solution (100ϫstock solution; Gibco) and incubated at 37°C in 3.5% CO 2 for 24 h. After removal of medium from the culture chambers, 4ϫ10 4 sporozoites were added in 100 µl of fresh supplemented medium. Three hours later, medium was replaced by fresh complete medium. Cultures were fixed with cold methanol after 21 h of incubation for antibody titration assays or 45 h for sera inhibition assays.
Antibody titration assays
Two days before challenge, sera of immunized mice were collected. In one experiment, sera were collected 2 weeks after a sporozoite challenge. Antibody titers were determined by ELISA using peptides as antigen (21) or by indirect immunofluorescence (IF) using methanol-fixed sporozoites or malaria hepatic stages as antigens. Titers were expressed as the reciprocal of the highest positive serum dilution.
Effects of sera on development of pre-erythrocytic stages Sera (dilutions 1:10) were added to hepatocyte cultures at the time of sporozoite inoculation and removed 3 h later. Sera from mice immunized with adjuvant alone were used as control. Schizont numbers were assessed in triplicate cultures by IF using hyperimmune sera recognizing Pyy liver stages. Percent inhibition was calculated by comparing the numbers of parasites in the experimental cultures with the numbers in control wells.
Effector lymphocytes
Lymph nodes (LN) were excised 1 week after the last peptide boost and processed in a tissue grinder. LN cell suspension was passed through nylon mesh, washed twice by centrifugation at 300 g and resuspended in supplemented William's E medium. LN cells were incubated overnight in culture flasks previously coated with FCS. Non-adherent cells were recovered in supplemented medium. Then, B cells were removed by incubating LN cells with culture supernatant of RA36B2, a hybridoma secreting anti-B220 mAb (ATCC TIB 146), for 30 min at 4°C. Cells were washed and freshly prepared complement (Low-Tox rabbit complement; Cedarlane, Hornby, Ontario, Canada) was added at a 10% final concentration. After 45 min of incubation at 37°C, cells were washed and resuspended in supplemented medium. B cell depletion was analyzed by flow cytometry (FACScan; Becton Dickinson, Mountain View, CA) and was always Ͼ90%.
In vitro assay of parasite liver stage elimination by effector lymphocytes
In this assay, 3 h after sporozoite inoculation, medium was replaced and different quantities of LN cells from control or peptide-immunized mice were added in supplemented medium. Cultures were incubated for 45 h with a change of 50 µl of medium 24 h after sporozoite inoculation. Schizont numbers were assessed in triplicate cultures by IF using hyperimmune sera recognizing P. yoelii liver stages. Percent inhibition was calculated by comparing the numbers of parasites in the experimental cultures with the numbers in control wells.
In vivo depletion of CD4 ϩ or CD8 ϩ T cells Hybridomas producing anti-CD4 GK1.5 (ATCC TIB 207) and anti-CD8 2.43 (ATCC TIB 210) rat IgG2b were kindly provided by G. Milon (Institut Pasteur, Paris, France). Antibodies were purified from ascitic fluid of CD1 nude mice (Charles River) by successive precipitation with PEG 30% and ammonium sulfate 50% (29) . Purity was assessed by SDS-PAGE. In vivo cell depletion was confirmed by flow cytometry analysis of spleen and LN cells from mice injected i.p. with 300 µg of purified antibody during 3 days. Experimental immunized mice were treated during 3 days just before sporozoite challenge.
Results
Protection against a challenge of Pyy sporozoites after peptide immunization BALB/c mice were immunized with linear peptides or MAP containing the T epitope (Py1T) and/or the B epitope (Py3 or Py4) from Pyy CSP and then challenged with 4000 or 50,000 Pyy sporozoites. As controls, C3H/He mice which are nonresponders to either Py1, Py3 or Py4 sequences were used (21) . As shown in Table 1 , only peptides containing both T and B epitopes conferred a protection in BALB/c mice against a challenge with 4000 sporozoites. Respectively, 69 and 81% Table 2 . Antibodies were detected only in sera from groups of BALB/c mice immunized with Py1T-Py3 and MAP4-Py1T-Py3. The IF titer of pooled sera from MAP4-Py1T-Py3-immunized mice was clearly higher than the IF titer of pooled sera from Py1T-Py3-immunized mice (25,600 versus 3200 against sporozoite and 3200 versus 800 against hepatic stages respectively) correlating with protection observed in both groups (Table 1) .
To further define the role of antibodies in protection, titration of sera from individual mice was performed. Results revealed a close correlation between anti-parasite antibody titers and capacity to resist challenge with 4000 sporozoites (Fig. 2) .
Then, fine specificity of induced antibodies was characterized. To this end, individual sera from Py1T-Py3 and MAP4-Py1T-Py3-immunized mice were tested by ELISA titration using Py1, Py3 peptides and MAP4-Py1T-Py3 as antigens. Levels of anti-Py1 antibodies were negligible in all mice (data not shown). Antibody titers were found 10-to 100-fold greater when the MAP was used as antigen than titers found when Py3 antigen was used. This is in agreement with a previous report (30) . However, in both cases, a good correlation was observed between anti-parasite antibody levels and protection (Fig. 3) . 
Biological effects of anti-parasite antibodies induced by immunization
Pooled sera from control, linear or MAP4-Py1T-Py3-immunized BALB/c mice were tested for their activity on development of pre-erythrocytic stages. A strong inhibition (86 Ϯ 1%) was observed with a 1:10 dilution of a pool of anti-MAP sera (IF titer on sporozoite: 12,800). A 1:10 dilution of a pool of anti-linear peptide sera (IF titer on sporozoite: 3200) was also found to inhibit liver stage development, but inhibition was significantly lower (50 Ϯ 3%). No inhibition was observed with the control pool.
Role of T cells in protection induced by immunization with
Py1T-Py3 or MAP4-Py1T-Py3
Despite sterile immunity observed in the majority of linear or MAP4-Py1T-Py3-immunized mice challenged with 4000 sporozoites, pre-challenge sera failed to block totally in vitro development of pre-erythrocytic stages. We thus investigated whether T cells were implicated in the protection. In vitro, LN cells from mice immunized with the Py1T-Py3, MAP4-Py1T or MAP4-Py1-Py3 did not inhibit Pyy liver stages (data not shown). In vivo, depletion of CD4 ϩ or CD8 ϩ T cells did not have any effect on protection induced by immunization with the linear or MAP form of the conjugate Py1T-Py3 (Table 3) .
Specificity of protection
To further assess the absence of involvement of T cells in protection and the protective activity of antibodies, another approach was chosen. As the 59-71 amino acids sequence of CSP is identical in Pyy and Pyn strains, but Pyn repeats differ from Pyy repeats (26, 31) (Fig. 1) , challenges with Pyy or Pyn sporozoites were performed in mice immunized with MAP4-Py1T-Py3. All immunized mice developed a parasitemia when challenged with Pyn parasites, whereas 100% did not when challenged with Pyy sporozoites (Table  4) . Similarly, pooled sera from MAP-immunized mice were Boosting effect of sporozoite challenge
As a secondary response after sporozoite infection is not necessarily observed in peptide-immunized mice (32) , subsequent experiments were performed to test it in BALB/c mice after immunization with linear peptide or MAPcontaining T and B epitopes. Antibody titers against sporozoite were boosted by sporozoite challenge in mice immunized with both peptidic constructions, allowing them to be protected against a second challenge performed 1 month later (Table 5 ).
Discussion
In this paper, we have shown that it is possible to induce a protective immunity in BALB/c mice against a challenge with Pyy sporozoites by immunization with the linear peptide or MAP-containing defined T and B epitopes of the Pyy CSP ( Table 1 ). The degree of protection was strongly correlated with levels of anti-parasite and anti-repeat antibodies ( Table 2 , and Figs 2 and 3). These antibodies were induced only after immunization of BALB/c mice with peptides containing the T epitope (Py1T) coupled to the B epitope (Py3). Since the MAP construct of the hybrid peptide failed to overcome genetic restriction in nonresponding mice (C3H/He) (21), we concluded that induction of antibodies was strictly dependent of the T h epitope. Similar results were obtained with MAP constructs containing a B epitope (repeats) and a T epitope of the CSP of P. berghei (8, 10, 33) . Overcoming H-2 restriction was also observed in the P. yoelii model system by including heterologous T epitopes (11). Nevertheless, overcoming of H-2 restriction by MAP formulation per se was reported for the antibody response against P. falciparum NANP repeats (27, 34) . Since such a response was not observed in our and other models, the widespread responsiveness induced by MAP-containing P. falciparum repeats seems to be inherent to this sequence. In the present model, use of the MAP construction allowed us to induce higher levels of antibodies than did the linear form of the hybrid peptide (Table 2) , allowing mice to resist a challenge with a higher number of sporozoites (Table 1) . Increased immunogenicity by MAP constructs is now well known (27, (35) (36) (37) (38) . Antibodies induced by immunization with the linear or the MAP construct containing both the T h epitope and repeats had a strong inhibitory effect on in vitro development of pre-erythrocytic stages of the parasite, but they failed to block it totally. In view of this result, although we could not exclude an exclusive role of antibodies in protection since inhibition assays were performed with diluted sera, we decided to investigate the potential implication of cytotoxic T cells. We found that LN cells from mice immunized with Py1T-Py3 or MAP4-Py1T-Py3 did not inhibit Pyy liver stages in vitro. Moreover, protection obtained in immunized mice depleted of CD4 ϩ or CD8 ϩ T cells (Table  3 ) allowed us to speculate that cytotoxic T lymphocytes were not responsible, even in part, for the observed protection. These results are in agreement with the inability of immunization with MAP containing the Py1T epitope alone (MAP4-Py1T) or peptide Py1 to induce any protective response in vivo (Table 1) (39) . Conversely, Migliorini et al. (10) reported that the analogous T epitope of Py1T in the P. berghei CSP (amino acids position 57-70 and referred as to T1) assembled as a MAP was able to protect against a challenge of P. berghei sporozoites in the absence of antibodies. This confirms that important differences exist between different models and that extrapolation from one model to another must be cautious.
Lack of protection of MAP4-Py1T-Py3-immunized mice against a challenge with Pyn sporozoites (Table 4) , a parasite which has the same Py1T sequence as Pyy but a different repeat sequence (31) , allowed us to confirm that only anti-repeat antibodies raised by peptide immunization were responsible for the protection observed in our model.
In the P. yoelii system, protective anti-repeat antibodies were induced in mice immunized with a MAP including the CSP repeats as a B epitope and two T h epitopes from tetanus toxoid (11) . In these experiments, anti-repeat antibody levels decreased with time, and BALB/c and A/J mice were much less protected when rechallenged 6 weeks after the first challenge. However, a majority of C57BL/6 mice were still protected. It is known that the repeat sequence contained in the construct behaves as a B and a T epitope in this strain of mice (21) . This suggests that the presence of a T h epitope of the parasite rather than an heterologous T epitope in the construct is of importance in protection against a second challenge. In the P. berghei system, Chai et al. (33) have shown that anti-repeat antibody response induced by immunization with a MAP containing an homologous T epitope was boosted by injection of irradiated sporozoites. One interesting feature of our results is that the immunogenic responses induced by peptides containing both repeats and a T h epitope of the Pyy CSP were boosted by injection of live sporozoites, allowing mice to resist a reinfection. Although much less effective than the MAP construct in protecting against a primary massive challenge, the linear form induced a level of protection against rechallenge comparable or even better than the one induced by the MAP (Table 5 ). Since it has been shown in the field that infected mosquitoes do not inject Ͼ5-40 sporozoites (40) 
